Improving cell therapy for advanced prostate cancer treatment
Official title: Optimizing Cell Therapy to Counter Adaptive Resistance Mechanisms in Prostate Cancer
Funded at Philadelphia VA Medical Center · NIH-10980420 · Data updated 2026-11-12
This study is looking at new ways to use your own immune cells to fight advanced prostate cancer, especially when it doesn't respond to regular treatments, so you can get a more personalized approach that targets your specific cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Philadelphia VA Medical Center NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | November 1, 2023 |
| Project end | October 31, 2027 |
| Funding year | 2025 |
| NIH project number | 5I01BX006247-02 |
| Project ID | NIH-10980420 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adult men diagnosed with advanced prostate cancer who have not responded well to traditional therapies.
✕Less likely to help
Patients with early-stage prostate cancer or those whose cancer is not advanced may not benefit from this research.
What this research studies
This research focuses on enhancing cell therapy techniques to combat advanced prostate cancer, particularly in cases where the cancer has become resistant to standard treatments. The approach involves using engineered T lymphocytes that can specifically target and attack cancer cells. By understanding how tumors adapt to evade immune responses, the research aims to optimize these therapies for better patient outcomes. Patients may receive personalized treatment based on their unique cancer characteristics.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for advanced prostate cancer, potentially improving survival rates and quality of life for patients.
How similar studies have gone: Previous research has shown promising results with similar CAR T-cell therapies in other cancers, indicating potential for success in prostate cancer as well.
Where this research is happening
-
Philadelphia VA Medical Center
Philadelphia, United States Active
Researchers
- Principal investigator: Posey, Avery D. — Philadelphia VA Medical Center
- Study coordinator: Posey, Avery D.
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.